CN110139667A - 一种使胰高血糖素、胰岛素恢复正常平衡的方法 - Google Patents
一种使胰高血糖素、胰岛素恢复正常平衡的方法 Download PDFInfo
- Publication number
- CN110139667A CN110139667A CN201780078124.3A CN201780078124A CN110139667A CN 110139667 A CN110139667 A CN 110139667A CN 201780078124 A CN201780078124 A CN 201780078124A CN 110139667 A CN110139667 A CN 110139667A
- Authority
- CN
- China
- Prior art keywords
- plasminogen
- subject
- secretion
- diabetic subjects
- glucagon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract 16
- 102000051325 Glucagon Human genes 0.000 title claims abstract 12
- 108060003199 Glucagon Proteins 0.000 title claims abstract 12
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title claims abstract 12
- 229960004666 glucagon Drugs 0.000 title claims abstract 12
- 102000004877 Insulin Human genes 0.000 title claims abstract 8
- 108090001061 Insulin Proteins 0.000 title claims abstract 8
- 229940125396 insulin Drugs 0.000 title claims abstract 8
- 102000013566 Plasminogen Human genes 0.000 claims abstract 50
- 108010051456 Plasminogen Proteins 0.000 claims abstract 50
- 239000003814 drug Substances 0.000 claims abstract 13
- 229940079593 drug Drugs 0.000 claims abstract 8
- 206010012601 diabetes mellitus Diseases 0.000 claims 18
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 12
- 239000008103 glucose Substances 0.000 claims 12
- 230000028327 secretion Effects 0.000 claims 12
- 210000004369 blood Anatomy 0.000 claims 10
- 239000008280 blood Substances 0.000 claims 10
- 230000000694 effects Effects 0.000 claims 7
- 230000003511 endothelial effect Effects 0.000 claims 7
- 239000003146 anticoagulant agent Substances 0.000 claims 4
- 230000003914 insulin secretion Effects 0.000 claims 4
- 230000001737 promoting effect Effects 0.000 claims 4
- 210000002966 serum Anatomy 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 101000605403 Homo sapiens Plasminogen Proteins 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 102000009433 Insulin Receptor Substrate Proteins Human genes 0.000 claims 2
- 108010034219 Insulin Receptor Substrate Proteins Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000003178 anti-diabetic effect Effects 0.000 claims 2
- 230000002924 anti-infective effect Effects 0.000 claims 2
- 230000002785 anti-thrombosis Effects 0.000 claims 2
- 229940127219 anticoagulant drug Drugs 0.000 claims 2
- 239000003472 antidiabetic agent Substances 0.000 claims 2
- 229960005475 antiinfective agent Drugs 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 235000012054 meals Nutrition 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000017011 Glycated Hemoglobin A Human genes 0.000 claims 1
- 241000288906 Primates Species 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000890 drug combination Substances 0.000 claims 1
- IXZISFNWUWKBOM-ARQDHWQXSA-N fructosamine Chemical compound NC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O IXZISFNWUWKBOM-ARQDHWQXSA-N 0.000 claims 1
- 108091005995 glycated hemoglobin Proteins 0.000 claims 1
- 108010087750 lysyl-plasminogen Proteins 0.000 claims 1
- 108010049112 miniplasminogen Proteins 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000000291 postprandial effect Effects 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2016/110171 | 2016-12-15 | ||
| CNPCT/CN2016/110171 | 2016-12-15 | ||
| PCT/CN2017/089066 WO2018107706A1 (zh) | 2016-12-15 | 2017-06-19 | 一种使胰高血糖素、胰岛素恢复正常平衡的方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110139667A true CN110139667A (zh) | 2019-08-16 |
Family
ID=62557852
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780078124.3A Pending CN110139667A (zh) | 2016-12-15 | 2017-06-19 | 一种使胰高血糖素、胰岛素恢复正常平衡的方法 |
| CN201780078168.6A Pending CN110198732A (zh) | 2016-12-15 | 2017-06-19 | 一种促进胰岛素受体底物-2表达的方法 |
| CN201780078122.4A Pending CN110366426A (zh) | 2016-12-15 | 2017-06-19 | 一种促进胰岛素分泌的方法 |
| CN201780078131.3A Pending CN110121357A (zh) | 2016-12-15 | 2017-06-19 | 一种治疗糖尿病的新方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780078168.6A Pending CN110198732A (zh) | 2016-12-15 | 2017-06-19 | 一种促进胰岛素受体底物-2表达的方法 |
| CN201780078122.4A Pending CN110366426A (zh) | 2016-12-15 | 2017-06-19 | 一种促进胰岛素分泌的方法 |
| CN201780078131.3A Pending CN110121357A (zh) | 2016-12-15 | 2017-06-19 | 一种治疗糖尿病的新方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US11311607B2 (enExample) |
| EP (4) | EP3556390B1 (enExample) |
| JP (6) | JP7554557B2 (enExample) |
| CN (4) | CN110139667A (enExample) |
| CA (4) | CA3047177A1 (enExample) |
| DK (1) | DK3556383T5 (enExample) |
| ES (1) | ES2981141T3 (enExample) |
| TW (7) | TWI763680B (enExample) |
| WO (7) | WO2018107705A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017101870A1 (zh) | 2015-12-18 | 2017-06-22 | 深圳瑞健生命科学研究院有限公司 | 一种预防或治疗糖尿病性视网膜病变的方法 |
| CN109069567A (zh) | 2015-12-18 | 2018-12-21 | 泰伦基国际有限公司 | 一种预防或治疗糖尿病性神经损伤及其相关病症的方法 |
| CN108778307A (zh) | 2015-12-18 | 2018-11-09 | 泰伦基国际有限公司 | 一种预防和治疗糖尿病肾病的方法 |
| EP3391902B1 (en) | 2015-12-18 | 2023-10-18 | Talengen International Limited | Plasminogen for use in the treatment of diabetic angiocardiopathy |
| TWI763680B (zh) | 2016-12-15 | 2022-05-11 | 大陸商深圳瑞健生命科學硏究院有限公司 | 纖溶酶原在製備藥物中的用途 |
| EP3556380A4 (en) | 2016-12-15 | 2020-05-13 | Talengen International Limited | METHOD FOR PREVENTING AND TREATING FABRIC OF TISSUE AND ORGAN |
| ES3036897T3 (en) | 2017-06-19 | 2025-09-25 | Talengen Int Ltd | Plasminogen for use in treating parkinson's and alzheimer's disease |
| CN111411072B (zh) * | 2020-03-09 | 2022-10-11 | 同济大学 | SLC30A8基因表达下调的抗糖尿病胰岛β细胞及其应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999000420A1 (en) * | 1997-06-26 | 1999-01-07 | Karolinska Innovations Ab | Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo |
| CN101918548A (zh) * | 2007-11-29 | 2010-12-15 | 泰勒克里斯生物治疗学公司 | 重组修饰的纤溶酶 |
| WO2017077380A1 (en) * | 2015-11-03 | 2017-05-11 | Prometic Biotherapeutics, Inc. | Plasminogen replacement therapy for plasminogen-deficiency |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| GB8721951D0 (en) | 1987-09-18 | 1987-10-28 | Thrombosis Research Trust | Organic compounds |
| JP2764264B2 (ja) | 1987-10-01 | 1998-06-11 | 株式会社ミドリ十字 | 線溶活性増強剤 |
| AU4661493A (en) | 1992-07-01 | 1994-01-31 | Beth Israel Hospital Boston | Enhancement of thrombolytic therapy with deglycosylated plasminogen |
| DK125693D0 (enExample) | 1993-11-05 | 1993-11-05 | Novo Nordisk As | |
| DE4411143C2 (de) | 1994-03-30 | 1996-08-01 | Immuno Ag | Thrombosemittel |
| MX9708217A (es) | 1995-04-26 | 1997-12-31 | Childrens Medical Center | Fragmentos de angiostatina y angiostatina agregada y metodos de uso. |
| MX9800684A (es) | 1995-07-27 | 1998-04-30 | Genentech Inc | Formulacion de proteinas liofilizadas isotonicas estables. |
| US5955627A (en) | 1996-12-16 | 1999-09-21 | Kuraray Co., Ltd. | Process for the preparation of cyclopropylacetylene derivatives |
| JP3561154B2 (ja) | 1997-12-26 | 2004-09-02 | 株式会社東芝 | 放送受信装置および契約管理装置 |
| US6728260B2 (en) | 1998-06-26 | 2004-04-27 | Intel Corporation | Switch and/or router unit |
| JP4577992B2 (ja) | 1998-09-29 | 2010-11-10 | リューベン・リサーチ・アンド・デベロップメント・ベー・ゼット・ウェー | 虚血性卒中の処置用の組成物を調製するための、α２抗プラスミンをインビボで減少する化合物の使用 |
| WO2000044391A2 (en) | 1999-01-28 | 2000-08-03 | The Children's Medical Center Corporation | Plasminogen kringle 4 region fragments and methods of use |
| US6733750B1 (en) | 1999-03-09 | 2004-05-11 | Minu, L.L.C. | Process and composition for inducing posterior vitreous detachment |
| US6899877B2 (en) | 1999-03-09 | 2005-05-31 | Minu, L.L.C. | Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina |
| US20030014787P1 (en) | 1999-03-31 | 2003-01-16 | Olesen L. Pernille | Floribunda rose variety 'POULfeld' |
| AU1191001A (en) | 1999-10-07 | 2001-05-10 | Human Genome Sciences, Inc. | Plasminogen-like polynucleotides, polypeptides, and antibodies |
| US6964764B2 (en) | 1999-11-13 | 2005-11-15 | Talecris Biotherapeutics, Inc. | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin |
| US20020159992A1 (en) | 2000-09-29 | 2002-10-31 | Jack Henkin | Antiangiogenic polypeptides and methods for inhibiting angiogenesis |
| TWI240723B (en) | 2001-06-20 | 2005-10-01 | Wyeth Corp | Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) |
| TWI224101B (en) | 2001-06-20 | 2004-11-21 | Wyeth Corp | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) |
| US6596785B2 (en) | 2001-07-17 | 2003-07-22 | Foamex L.P. | Ink retaining foam structure |
| US7067492B2 (en) | 2001-09-06 | 2006-06-27 | Omnio Ab | Method of promoting healing of a tympanic membrane perforation |
| US20030198666A1 (en) | 2002-01-07 | 2003-10-23 | Richat Abbas | Oral insulin therapy |
| US7202066B2 (en) | 2002-01-29 | 2007-04-10 | Carrington Laboratories, Inc. | Combination of a growth factor and a protease enzyme |
| MXPA04007585A (es) | 2002-02-06 | 2005-09-20 | N Zyme Biotec Gmbh | Metodo para la produccion de proteinas recombinantes en microorganismos. |
| US6787135B2 (en) | 2002-03-13 | 2004-09-07 | William Beaumont Hospital | Modification of vitreal matrix metalloproteinase activity |
| EP2322200A3 (en) | 2002-10-29 | 2011-07-27 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| GB0228409D0 (en) | 2002-12-06 | 2003-01-08 | Thromb X Nv | Pharmacological vitreolysis |
| CN1451746A (zh) | 2003-03-20 | 2003-10-29 | 广州市启源生物科技有限公司 | 人纤溶酶原Kringle 5缺失突变重组多肽 |
| US7075933B2 (en) | 2003-08-01 | 2006-07-11 | Nortel Networks, Ltd. | Method and apparatus for implementing hub-and-spoke topology virtual private networks |
| JP4740531B2 (ja) | 2003-09-30 | 2011-08-03 | 雪印乳業株式会社 | 骨吸収抑制剤 |
| US20050250694A1 (en) | 2003-10-10 | 2005-11-10 | Ma Jian-Xing | Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same |
| CN1946352A (zh) | 2004-04-09 | 2007-04-11 | 狄科特康坦特公司 | 递送药物至眼以治疗后段疾病的方法和物品 |
| ES2349555T3 (es) | 2004-04-22 | 2011-01-05 | Talecris Biotherapeutics, Inc. | Plasmina modificada recombinántemente. |
| AU2005277137A1 (en) | 2004-08-23 | 2006-03-02 | Wyeth | Pyrrolo-naphthyl acids as PAI-1 inhibitors |
| AU2005277138A1 (en) | 2004-08-23 | 2006-03-02 | Wyeth Holdings Corporation | Oxazolo-naphthyl acids as plaminogen activator inhibtor type-1 (PAI-1) modulators useful in the treatment of thrombosis and cardiovascular diseases |
| CN101227918A (zh) | 2005-04-29 | 2008-07-23 | 加州大学评议会 | 治疗以炎症反应为特征的病理的肽和肽模拟物 |
| US20060257391A1 (en) | 2005-05-11 | 2006-11-16 | Bausch & Lomb Incorporated | Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions |
| US8064439B2 (en) | 2005-06-30 | 2011-11-22 | Cisco Technology, Inc. | Method and system for call processing |
| MX2008002117A (es) | 2005-08-17 | 2008-09-26 | Wyeth Corp | Indoles sustituidos y metodos de uso de estos. |
| US8741260B2 (en) | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
| WO2007051314A1 (en) | 2005-11-07 | 2007-05-10 | American Diagnostica Inc. | Curcuminoid compounds for inhibiting plasminogen activator inhibitor-1 |
| CN100529085C (zh) | 2005-12-30 | 2009-08-19 | 上海新生源医药研究有限公司 | 重组人纤溶酶原Kringle 5(hk5)生产方法 |
| CN101002888A (zh) | 2006-01-16 | 2007-07-25 | 陈维森 | 复方糖尿康 |
| US20070196350A1 (en) | 2006-02-22 | 2007-08-23 | Bartels Stephen P | Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment |
| CN101573134B (zh) * | 2006-08-28 | 2013-03-06 | 李季男 | 抗感染候选药物 |
| US20100080773A1 (en) | 2008-09-26 | 2010-04-01 | Sdg, Inc. | Orally Bioavailable Lipid-Based Constructs |
| CN101842093B (zh) | 2007-10-23 | 2012-08-22 | 株式会社医药分子设计研究所 | Pai-1产生抑制剂 |
| US20090208448A1 (en) * | 2008-02-15 | 2009-08-20 | Solomon Keith R | Inhibition of angiogenesis |
| JP2009196927A (ja) | 2008-02-21 | 2009-09-03 | Chemo Sero Therapeut Res Inst | 血管障害に起因する網膜障害の進展阻害または治療剤 |
| WO2010125148A2 (en) | 2009-04-30 | 2010-11-04 | Catherine Blondel | Methods for treating ocular conditions |
| NZ597452A (en) | 2009-07-10 | 2013-10-25 | Thrombogenics Nv | Variants of plasminogen and plasmin |
| CN102250210B (zh) | 2010-05-21 | 2014-05-28 | 厦门大学 | 人纤溶酶原Kringle 5短肽、其药物组合物、用途和编码该种短肽的多核苷酸 |
| CN102121023B (zh) | 2010-12-22 | 2012-07-04 | 中山大学 | 突变型人纤溶酶原kringle5及其制备方法及应用 |
| RU2604807C2 (ru) | 2011-01-05 | 2016-12-10 | ТромбоДженикс НВ | Варианты плазминогена и плазмина |
| CN102154253A (zh) | 2011-01-06 | 2011-08-17 | 郑州大学 | 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途 |
| CA2844644A1 (en) * | 2011-08-12 | 2013-02-21 | Thrombogenics N.V. | Plasminogen and plasmin variants |
| WO2014070983A1 (en) | 2012-10-31 | 2014-05-08 | The Regents Of The University Of Michigan | Plasminogen activator-1 inhibitors and methods of use thereof |
| EA033403B1 (ru) * | 2013-08-13 | 2019-10-31 | Sanofi Sa | Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения |
| KR102393711B1 (ko) | 2013-10-17 | 2022-05-04 | 더 제너럴 하스피탈 코포레이션 | 자가면역 질환의 치료에 반응하는 대상체의 식별 방법 및 그의 치료를 위한 조성물 |
| CN104789544B (zh) * | 2014-01-16 | 2019-11-26 | 中国科学院福建物质结构研究所 | 重组pai-1抑制剂、包含其的组合物及其用于治疗和检测用途 |
| HUE068351T2 (hu) | 2014-12-19 | 2024-12-28 | Kedrion Biopharma Inc | Plazminogént tartalmazó gyógyszerkészítmény és annak felhasználásai |
| CN115845037A (zh) | 2015-12-18 | 2023-03-28 | 泰伦基国际有限公司 | 一种用于预防或治疗急性及慢性血栓的方法 |
| CN108778307A (zh) | 2015-12-18 | 2018-11-09 | 泰伦基国际有限公司 | 一种预防和治疗糖尿病肾病的方法 |
| WO2017101870A1 (zh) | 2015-12-18 | 2017-06-22 | 深圳瑞健生命科学研究院有限公司 | 一种预防或治疗糖尿病性视网膜病变的方法 |
| CN109069567A (zh) | 2015-12-18 | 2018-12-21 | 泰伦基国际有限公司 | 一种预防或治疗糖尿病性神经损伤及其相关病症的方法 |
| TW201822809A (zh) | 2016-12-15 | 2018-07-01 | 深圳瑞健生命科學硏究院有限公司 | 一種預防和治療高脂血症的方法 |
| TWI763680B (zh) | 2016-12-15 | 2022-05-11 | 大陸商深圳瑞健生命科學硏究院有限公司 | 纖溶酶原在製備藥物中的用途 |
| CN111465408B (zh) | 2017-12-15 | 2023-07-04 | 泰伦基国际有限公司 | 一种预防或治疗骨关节炎的方法和药物 |
-
2017
- 2017-06-19 TW TW106120481A patent/TWI763680B/zh active
- 2017-06-19 JP JP2019532019A patent/JP7554557B2/ja active Active
- 2017-06-19 TW TW106120493A patent/TWI763681B/zh active
- 2017-06-19 US US16/469,817 patent/US11311607B2/en active Active
- 2017-06-19 CN CN201780078124.3A patent/CN110139667A/zh active Pending
- 2017-06-19 TW TW106120480A patent/TWI738799B/zh active
- 2017-06-19 EP EP17881683.1A patent/EP3556390B1/en active Active
- 2017-06-19 EP EP17882072.6A patent/EP3556392B1/en active Active
- 2017-06-19 TW TW106120494A patent/TWI669130B/zh active
- 2017-06-19 JP JP2019532043A patent/JP7554048B2/ja active Active
- 2017-06-19 JP JP2019531895A patent/JP7171572B2/ja active Active
- 2017-06-19 EP EP17880563.6A patent/EP3556384B1/en active Active
- 2017-06-19 JP JP2019532017A patent/JP7175270B2/ja active Active
- 2017-06-19 WO PCT/CN2017/089065 patent/WO2018107705A1/zh not_active Ceased
- 2017-06-19 CN CN201780078168.6A patent/CN110198732A/zh active Pending
- 2017-06-19 TW TW106120484A patent/TW201822803A/zh unknown
- 2017-06-19 US US16/470,120 patent/US11129880B2/en active Active
- 2017-06-19 CA CA3047177A patent/CA3047177A1/en not_active Abandoned
- 2017-06-19 CN CN201780078122.4A patent/CN110366426A/zh active Pending
- 2017-06-19 WO PCT/CN2017/089061 patent/WO2018107701A1/zh not_active Ceased
- 2017-06-19 US US16/470,117 patent/US20190314464A1/en not_active Abandoned
- 2017-06-19 DK DK17880561.0T patent/DK3556383T5/da active
- 2017-06-19 CA CA3047176A patent/CA3047176C/en active Active
- 2017-06-19 WO PCT/CN2017/089066 patent/WO2018107706A1/zh not_active Ceased
- 2017-06-19 WO PCT/CN2017/089069 patent/WO2018107708A1/zh not_active Ceased
- 2017-06-19 TW TW106120482A patent/TWI644682B/zh active
- 2017-06-19 CA CA3047172A patent/CA3047172A1/en not_active Abandoned
- 2017-06-19 WO PCT/CN2017/089063 patent/WO2018107703A1/zh not_active Ceased
- 2017-06-19 US US16/469,845 patent/US20190307861A1/en not_active Abandoned
- 2017-06-19 ES ES17880561T patent/ES2981141T3/es active Active
- 2017-06-19 WO PCT/CN2017/089064 patent/WO2018107704A1/zh not_active Ceased
- 2017-06-19 WO PCT/CN2017/089062 patent/WO2018107702A1/zh not_active Ceased
- 2017-06-19 CA CA3047173A patent/CA3047173A1/en not_active Abandoned
- 2017-06-19 CN CN201780078131.3A patent/CN110121357A/zh active Pending
- 2017-06-19 TW TW106120485A patent/TWI642442B/zh active
- 2017-06-19 EP EP17880561.0A patent/EP3556383B1/en active Active
-
2022
- 2022-07-27 JP JP2022119582A patent/JP2022166028A/ja active Pending
- 2022-07-27 JP JP2022119543A patent/JP2022166026A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999000420A1 (en) * | 1997-06-26 | 1999-01-07 | Karolinska Innovations Ab | Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo |
| CN101918548A (zh) * | 2007-11-29 | 2010-12-15 | 泰勒克里斯生物治疗学公司 | 重组修饰的纤溶酶 |
| WO2017077380A1 (en) * | 2015-11-03 | 2017-05-11 | Prometic Biotherapeutics, Inc. | Plasminogen replacement therapy for plasminogen-deficiency |
Non-Patent Citations (4)
| Title |
|---|
| ARTHUR MIRSK等: "The destruction of glucagon, adrenocorticotropin and somatotropin by human blood plasma", 《THE JOURNAL OF CLINICAL INVESTIGATION》 * |
| AURELIA LUGEA等: "Pancreas Recovery Following Caerulein-induced Pancreatitis is Impaired in Plasminogen Deficient Mice", 《GASTROENTEROLOGY》 * |
| BUTERA D等: "plasminogen isoform 1 precursor [Homo sapiens]", 《GENBANK》 * |
| RAMZI A. AJJAN等: "Diabetes is associated with posttranslational modifications in plasminogen resulting in reduced plasmin generation and enzyme-specific activity", 《BLOOD》 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110139667A (zh) | 一种使胰高血糖素、胰岛素恢复正常平衡的方法 | |
| Van Gaal et al. | Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program | |
| TWI469787B (zh) | 胰島素長效調配物 | |
| US20250064898A1 (en) | Insulin glargine/lixisenatide fixed ratio formulation | |
| Nauck et al. | Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study | |
| JP6033280B2 (ja) | ＰＴＨ、ＰＴＨｒＰ、および関連ペプチドの薬剤送達方法 | |
| CN102026666B (zh) | 促胰岛素肽缀合物制剂 | |
| EP1965823B1 (en) | Methods for administering hypoglycemic agents | |
| JP2020502151A5 (enExample) | ||
| Keating | Insulin degludec and insulin degludec/insulin aspart: a review of their use in the management of diabetes mellitus | |
| JP2012530768A (ja) | インスリン、ニコチンアミド及びアミノ酸を含む製剤 | |
| JP2009503093A5 (enExample) | ||
| JP2020510628A5 (enExample) | ||
| JP2024524273A (ja) | マズチドの使用 | |
| WO2020186108A1 (en) | FORMULATION INCLUDING A COMBINATION OF β-ENDORPHIN AND ADRENOCORTICOTROPIC HORMONE | |
| CN106117370A (zh) | 高糖基化Exendin‑4及其类似物的融合蛋白、其制备方法和用途 | |
| Alzahrani et al. | Molecular Pharmacology of Glucagon-Like Peptide 1-Based Therapies in the Management of Type Two Diabetes Mellitus and Obesity | |
| KR20250021331A (ko) | mazdutide를 사용하는 치료 방법 | |
| Kaur et al. | Translational aspects of glucagon: Current use and future prospects | |
| Roy | Administration of once-daily canagliflozin to a non-diabetic patient in addition to standard aerobic exercise: a case report | |
| CN101766811B (zh) | 艾塞那肽或其类似物在制备治疗或预防糖尿病合并脑梗塞药物中的用途 | |
| Steyn | Xultophy® | |
| Oh et al. | Correction of anemia with continuous erythropoietin receptor activator in Korean patients on long-term hemodialysis | |
| Cypryk et al. | New faster-acting insulin Fiasp®—do we need a new meal-time insulin? | |
| Sinha et al. | Is insulin degludec a more effective treatment for patients using high doses of insulin glargine but not attaining euglycemia? Some case reports from India |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |